SDC1 and breast carcinoma: For example, syndecan-1 that is expressed on AML cells, is a therapeutic target under investigation in multiple myeloma [139], while the inhibition of ILK has been tested in chronic lymphocytic leukaemia, prostate, and breast cancer cell lines [140].